SABS - SAB Biotherapeutics surges ~85% on FDA fast track tag for influenza drug SAB-176

2023-04-13 09:44:17 ET

• SAB Biotherapeutics' ( NASDAQ: SABS ) stock rose ~87% on Thursday after the company said the U.S Food and Drug Administration (FDA) granted fast track designation to influenza therapy SAB-176.
• The company noted SAB-176 is a first fully-human broadly neutralizing immunoglobulin antibody therapy aimed to prevent or reduce severe outcomes of Type A and Type B influenza infection in patients at high risk for severe complications, including in patients who are immunocompromised.
• SAB added that it also received FDA guidance and regulatory alignment on advancing SAB-176 into the next phase of development via starting a phase 2b trial in patient populations at high-risk for developing severe disease.
• In a phase 2a challenge study, SAB-176 showed broad cross protection which included strains that were not specifically targeted in the manufacturing of the therapy, according to the company.

For further details see: